NCT06761066Enrolling by invitation
Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
36-week, Single-center, Randomized, Double-blind, Parallel-design, Placebo-controlled Trial to Determine the Safety and Efficacy of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
The purpose of this clinical trial is to exploratively evaluate the efficacy and safety of NVP -NK4146 in improving mild cognitive impairment (MCI) in patients with due to Alzheimer's disease (AD) compared to placebo
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 17 Dec 2024
- Start date
- 20 Jan 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- NVP Healthcare
- Diseases
- Alzheimer disease
- NCT number
- NCT06761066
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 20 Jan 2026 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject currently receiving treatment for malignant tumors (except those who have fully recovered from cancer for more than 5 years or those with basal cell carcinoma, squamous cell carcinoma, or prostate cancer may participate at the investigator's discretion)
Other illness
- Subject diagnosed with dementia according to the criteria of DSM-5 or ICD-10
Other
- Subject who are illiterate and/or without any education
- Any other factors deemed by the investigator to be likely to ineligible for the study
Who the study is looking for
- Male and female adults aged 60 or older
- Subject who meet the National Institute of Aging and Alzheimer's Associations (NIA-AA) core clinical criteria for MCI and have positive readings from amyloid PET
- Subject who can read and understand the Informed Consent Form and legends and who voluntarily decided to participate in current clinical trial and have signed the Informed Consent Form
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Catholic University of Korea Yeouido St. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.